As the therapeutic arsenal for type 2 diabetes mellitus (T2DM) continues to evolve, the role of basal insulin (BI) is being redefined-not as a default next step, but as a precision tool integrated thoughtfully into personalized diabetes care.

      This comprehensive review explores the modern-day relevance of BI amidst newer agents like GLP-1 receptor agonists and SGLT2 inhibitors. While these agents boast benefits such as weight loss, minimal titration, and cardiorenal protection, BI retains its vital role in controlling fasting plasma glucose and preventing long-term vascular complications—particularly in patients with progressive insulin deficiency, acute metabolic stress, or advanced disease stages.

The article outlines:
• Mechanisms of BI in suppressing hepatic glucose output, modulating glucagon, and reducing lipotoxicity.
• Innovations in BI formulations, including second-generation analogs (e.g., glargine-300, degludec) and once-weekly options like icodec.
• Clinical settings favoring BI-from pregnancy and LADA to cases with comorbidities or GLP-1/SGLT2 intolerance.
• Combinational use of BI with GLP-1 RAs or SGLT2is, offering complementary glucose-lowering and cardiometabolic benefits.
• Barriers and mitigation strategies for hypoglycemia and weight gain, including conservative titration algorithms and patient education.
• Landmark trials like ORIGIN and GRADE that demonstrate BI’s safety, efficacy, and even remission potential when initiated early.

      Ultimately, the authors call for a shift from “either-or” to “and-also” thinking-placing BI not in competition with newer therapies, but as an essential ally when individualized care demands it. In many cases, it may be the missing piece to sustain glycemic control and reduce complications in the long term.